Search Results Search Sort by RelevanceMost Recent Case and Commentary Nov 2004 Heads or Tails: Randomized Placebo-Controlled Trials, Commentary 1 Charles Weijer, MD, PhD Virtual Mentor. 2004;6(11):482-484. doi: 10.1001/virtualmentor.2004.6.11.ccas2-0411. Case and Commentary Nov 2004 Heads or Tails: Randomized Placebo-Controlled Trials, Commentary 2 Karen Kreiner, MD Virtual Mentor. 2004;6(11):484-485. doi: 10.1001/virtualmentor.2004.6.11.ccas2-0411. Medicine and Society Oct 2023 What Might Aducanumab Teach Us About Clinicians’ Judgment About Whether to Recommend Emerging Alzheimer’s Interventions? Adam W. Burroughs, MD and Lewis P. Krain, MD Ethics questions about care of patients with AD could influence clinicians’ judgment about whether and when to recommend aducanumab. AMA J Ethics. 2023;25(10):E777-782. doi: 10.1001/amajethics.2023.777.
Case and Commentary Nov 2004 Heads or Tails: Randomized Placebo-Controlled Trials, Commentary 1 Charles Weijer, MD, PhD Virtual Mentor. 2004;6(11):482-484. doi: 10.1001/virtualmentor.2004.6.11.ccas2-0411.
Case and Commentary Nov 2004 Heads or Tails: Randomized Placebo-Controlled Trials, Commentary 2 Karen Kreiner, MD Virtual Mentor. 2004;6(11):484-485. doi: 10.1001/virtualmentor.2004.6.11.ccas2-0411.
Medicine and Society Oct 2023 What Might Aducanumab Teach Us About Clinicians’ Judgment About Whether to Recommend Emerging Alzheimer’s Interventions? Adam W. Burroughs, MD and Lewis P. Krain, MD Ethics questions about care of patients with AD could influence clinicians’ judgment about whether and when to recommend aducanumab. AMA J Ethics. 2023;25(10):E777-782. doi: 10.1001/amajethics.2023.777.